These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22043050)

  • 1. Surrogate markers for targeted therapy-based treatment activity and efficacy.
    Bianchini G; Gianni L
    J Natl Cancer Inst Monogr; 2011; 2011(43):91-4. PubMed ID: 22043050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Metzger-Filho O; de Azambuja E
    J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers predicting clinical benefit: fact or fiction?
    Guarneri V; Barbieri E; Conte P
    J Natl Cancer Inst Monogr; 2011; 2011(43):63-6. PubMed ID: 22043043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene profiling assay and application: the predictive role in primary therapy.
    Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
    J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.
    Generali D; Symmans WF; Berruti A; Fox SB
    J Natl Cancer Inst Monogr; 2011; 2011(43):99-102. PubMed ID: 22043052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermediate endpoints of primary systemic therapy in breast cancer patients.
    Berruti A; Generali D; Bertaglia V; Brizzi MP; Mele T; Dogliotti L; Bruzzi P; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):142-6. PubMed ID: 22043062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
    von Minckwitz G; Loibl S; Maisch A; Untch M
    Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy as a platform for drug development and approval in breast cancer.
    Bardia A; Baselga J
    Clin Cancer Res; 2013 Dec; 19(23):6360-70. PubMed ID: 24298066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HER2 World: Better Treatment Selection for Better Outcome.
    Tagliabue E; Campiglio M; Pupa SM; Balsari A; Ménard S
    J Natl Cancer Inst Monogr; 2011; 2011(43):82-5. PubMed ID: 22043048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive markers of response to neoadjuvant chemotherapy in breast cancer.
    Tewari M; Krishnamurthy A; Shukla HS
    Surg Oncol; 2008 Dec; 17(4):301-11. PubMed ID: 18467090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial.
    Yamaguchi T; Mukai H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1211-4. PubMed ID: 23129778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.